Key Insights

Highlights

Success Rate

67% trial completion

Treatment Research

4 treatments under study, led by Artemetherlumefantrine

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 54/100

Termination Rate

25.0%

1 terminated out of 4 trials

Success Rate

66.7%

-19.9% vs benchmark

Late-Stage Pipeline

100%

4 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed with results

Key Signals

1 with results67% success

Data Visualizations

Phase Distribution

4Total
Phase 3 (1)
Phase 4 (3)

Trial Status

Completed2
Unknown1
Terminated1

Trial Success Rate

66.7%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT00386750Phase 4Terminated

Safety of Artemether - Lumefantrine, and Other Malaria Drugs and Their Effect on the Auditory Function

NCT00444106Phase 4Completed

Evaluation of Potential Effect of Artemether - Lumefantrine and Malaria Drugs on Auditory Function

NCT00137566Phase 4Unknown

The Effect of Paracetamol in the Treatment of Non-severe Malaria in Children in Guinea-Bissau

NCT00386763Phase 3Completed

Efficacy and Safety of the Pediatric Formulation of Artemether- Lumefantrine in Children With Uncomplicated P. Falciparum Malaria.

Showing all 4 trials

Research Network

Common Treatments

  • Artemetherlumefantrine3
  • Atovaquoneproguanil1
  • Acetaminophen1
  • Artesunatemefloquine1

Active Sponsors

  • Novartis2
  • Novartis Pharmaceuticals1
  • Bandim Health Project1

Top Investigators

Related Conditions

  • Malaria4

Activity Timeline